Anti-HMGB1 Antibody Therapy Ameliorates Spinal Cord Ischemia–Reperfusion Injury in Rabbits
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26178643 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Genya Muraoka und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. Hauptthemen laut MEDLINE: Reperfusion Injury, HMGB1 Protein, Antibodies, Monoclonal, Spinal Cord Ischemia. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KAKENHI.
Abstract (Originalsprache)
Spinal cord ischemia–reperfusion (SCI/R) injury remains a major clinical challenge with limited therapeutic options. High-mobility group box 1 (HMGB1), a proinflammatory mediator released during cellular stress, has been implicated in the pathogenesis of ischemia–reperfusion-induced neural damage. In this study, we investigated the neuroprotective potential of the anti-HMGB1 monoclonal antibody (mAb) in a rabbit model of SCI/R injury. Male New Zealand White rabbits were anesthetized and subjected to 11 min of abdominal aortic occlusion using a micro-bulldog clamp following heparinization. Anti-HMGB1 mAb or control IgG was administered intravenously immediately after reperfusion and again at 6 h post-reperfusion. Neurological function was assessed at 6, 24, and 48 h after reperfusion using the modified Tarlov scoring system. The rabbits were euthanized 48 h after reperfusion for spinal cord and blood sampling. Treatment with anti-HMGB1 mAb significantly improved neurological outcomes, reduced the extent of spinal cord infarction, preserved motor neuron viability, and decreased the presence of activated microglia and infiltrating neutrophils. Furthermore, it attenuated apoptosis, oxidative stress, and inflammatory responses in the spinal cord, and helped maintain the integrity of the blood–spinal cord barrier. These findings suggest that anti-HMGB1 mAb may serve as a promising therapeutic agent for SCI/R injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
- Department of Translational Research, Center for Innovative Clinical Medicine, Medical Development Field, Okayama University, Okayama 700-8558, Japan.
- Department of Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.
- Department of Medical Technology, Faculty of Science, Okayama University of Science, Okayama 700-0005, Japan.
- Division of Medical Safety Management, Safety Management Facility, Okayama University Hospital, Okayama 700-8558, Japan.
- Department of Cardiovascular Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.
ORCID-Profile: Yasuhiro Fujii, Dengli Wang, Daiki Ousaka
Förderung
- KAKENHI
Zitieren
APA
Muraoka, G., Fujii, Y., Liu, K., Qiao, H., Wang, D., Ousaka, D., Oozawa, S., Kasahara, S., & Nishibori, M. (2025). Anti-HMGB1 Antibody Therapy Ameliorates Spinal Cord Ischemia–Reperfusion Injury in Rabbits. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178643
Vancouver
Muraoka G, Fujii Y, Liu K, Qiao H, Wang D, Ousaka D, et al. Anti-HMGB1 Antibody Therapy Ameliorates Spinal Cord Ischemia–Reperfusion Injury in Rabbits. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178643
BibTeX
@article{Muraoka2025,
author = {Muraoka, Genya and Fujii, Yasuhiro and Liu, Keyue and Qiao, Handong and Wang, Dengli and Ousaka, Daiki and Oozawa, Susumu and Kasahara, Shingo and Nishibori, Masahiro},
title = {Anti-HMGB1 Antibody Therapy Ameliorates Spinal Cord Ischemia–Reperfusion Injury in Rabbits},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26178643}
}
EUVIMED